Ipamorelin – 10 Vials (CAS: 170851-70-4)

Price range: $294.00 through $327.00

Ipamorelin is a selective pentapeptide growth hormone secretagogue (GHS) that acts as a ghrelin receptor (GHS-R1a) agonist. This high-purity lyophilized powder is widely researched for its ability to stimulate pulsatile growth hormone release with minimal effect on ACTH or cortisol. Supplied for laboratory research use only.

Description

Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂ (MW 711.86 Da) . It was derived from GHRP-1 and developed as the first highly selective growth hormone secretagogue . Ipamorelin acts as an agonist at the ghrelin receptor (GHS-R1a) in the hypothalamus and pituitary, stimulating growth hormone (GH) secretion through a mechanism distinct from GHRH .

This product is supplied as a sterile lyophilized powder and is intended strictly for research purposes only. It is NOT for human or veterinary consumption.

 

Key Research Focus

Ipamorelin has been investigated in preclinical and clinical research exploring its roles in:

  • Selective GH Secretion: In vitro, ipamorelin concentration-dependently increases GH release from rat pituitary cells with a potency of approximately 1.3 nM . In vivo, GH secretagogue potency is approximately 80 nmol/kg in rats and 2.3 nmol/kg in swine . Unlike GHRP-6 and GHRP-2, ipamorelin does not significantly stimulate ACTH or cortisol secretion, making it a cleaner research tool for isolating GH-specific effects .
  • Gastrointestinal Motility (Postoperative Ileus): Preclinical studies in rodent models of postoperative ileus (POI) demonstrated that repetitive intravenous dosing of ipamorelin (0.1 or 1 mg/kg) significantly increased cumulative fecal pellet output, food intake, and body weight gain over 48 hours post-surgery . A single dose decreased time to first bowel movement but did not affect fecal output or body weight .
  • Visceral Hypersensitivity: In a rat model of colonic hypersensitivity, ipamorelin (IV, 0.01–1.0 mg/kg) caused dose-dependent reduction in colonic hypersensitivity and somatic allodynia, with statistical significance at 1.0 mg/kg .
  • Clinical Trial (Postoperative Ileus): A Phase 2 randomized, double-blind, placebo-controlled trial (NCT00672074) enrolled 117 patients undergoing bowel resection to evaluate IV ipamorelin (0.03 mg/kg twice daily) for POI. The median time to first tolerated meal was 25.3 hours (ipamorelin) versus 32.6 hours (placebo), a numerical but non-significant difference (p = 0.15). No significant differences were seen in key or secondary efficacy analyses. The regimen was well tolerated .
  • GH/IGF-1 Axis Under Glucocorticoid Exposure: In rats treated with methylprednisolone, repeated IV ipamorelin (0.4 or 1.6 mg/kg/day × 10 days) raised IGF-1 levels and significantly reduced glucocorticoid-induced weight loss (P < 0.05), supporting that the GH-IGF-1 axis remains responsive to GHS stimulation during glucocorticoid exposure .
  • Bone and Adiposity Research: Preclinical studies have demonstrated that ipamorelin induces longitudinal bone growth in hypophysectomized rats and increases bone mineral content in adult female rats . Additional research indicates GH secretagogues including ipamorelin stimulate adiposity-related changes in rodents through a GH-independent pathway .

 

Evidence Gap in Human Research

As of April 2026, only one completed peer-reviewed randomized controlled trial of ipamorelin in humans has been published (the 2014 POI study described above) . No completed human trials have examined ipamorelin’s effects on body composition, lean mass, bone density, recovery, or IGF-1 for GH-related endpoints . All GH-related efficacy data derive from preclinical models.

 

Product Specifications

  • Form: Lyophilized Powder (Sterile)
  • Purity: ≥98% (HPLC Verified)
  • Molecular Formula: C₃₈H₄₉N₉O₅
  • Molecular Weight: 711.86 Da
  • CAS Number: 170851-70-4
  • Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂
  • Storage: Store at -20°C (freezer) for long-term stability. Protect from light .
  • Solubility: Soluble in sterile water or buffer for laboratory use.
  • Disclaimer: This product is a chemical reagent for research purposes only. It is NOT for human or animal consumption, diagnostic, or therapeutic use. Ipamorelin is classified as a prohibited substance by the World Anti-Doping Agency (WADA).

 

Why Choose Ipamorelin?

Ipamorelin offers a selectively cleaner research tool compared to earlier GHS compounds (GHRP-2, GHRP-6, hexarelin) due to its lack of significant ACTH/cortisol stimulation . Its well-characterized GHS-R1a agonist mechanism, demonstrated effects on gastrointestinal motility and visceral hypersensitivity in preclinical models, and available human safety data from a Phase 2 trial provide a translational foundation for experimental design. Researchers should note the significant evidence gap: GH-related efficacy has not been established in human trials, and the one completed human RCT failed to meet its primary efficacy endpoint in postoperative ileus

Additional information

Grams

5mg*10vials, 10mg*10vials

Disclaimer: Supplied strictly as a high-purity chemical reagent for laboratory research and development use only. Not for human or animal consumption.